Back to dataset
UK Inflammatory Bowel Disease (IBD) audit: Round 4 (2012 - 2014)Data field description file adult biological therapies audit 2014
You're previewing the first 4 rows of this file.
Download this file| Column 1 | Column 2 | Column 3 | Column 4 | Column 5 | Column 6 | Column 7 | Column 8 | Column 9 |
|---|---|---|---|---|---|---|---|---|
| Health board / Trust name | Sitename | Number of patients with Crohn's disease entered at your site | Patients with Crohn's disease given 160/80 mg of ADA at induction | Response to treatment | Remission achieved | Patients with at least one adverse event | Patients with Crohn's disease on concomittant therapy, 5-ASA at induction | Patients with Crohn's disease, treatment effective and discontinued at follow-up |
| Name of Health Board / Trust | Name of site | No of Crohn's disease patients entered | No of Crohn's disease patients given 160/80 mg of ADA at induction | Percentage (%) of Crohn's disease patients with a HBI drop of >3 at any follow up between 10 and 14 weeks | Percentage (%) of Crohn's disease patients with a HBI score of <4 at any follow up between 10 and 14 weeks | Percentage of patients who experienced at least one adverse event | Percentage of all patients with Crohn's disease on 5-ASA as a concomittant therapy at initial treatment | Percentage of patients with Crohn's disease who had their treatment effective and discontinued at follow-up |
| text | text | integer | integer (Percentage) | integer (Percentage) | integer (Percentage) | integer (Percentage) | integer (Percentage) | integer (Percentage) |
| text | text | integer | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) |